Yahoo Finance • 15 hours ago
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story
Yahoo Finance • 7 days ago
MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheime... Full story
Yahoo Finance • last month
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate single-arm trial will assess safety... Full story
Yahoo Finance • 2 months ago
Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a ritonavir-free, protease in... Full story
Yahoo Finance • 2 months ago
NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human healt... Full story
Yahoo Finance • 3 months ago
Traws Pharma, Inc. (NASDAQ:TRAW), a small-cap biotech company with a market capitalization of $8.12 million, announced Thursday that Nora Brennan has notified the company of her decision to resign from her role as Interim Chief Financial O... Full story
Yahoo Finance • 3 months ago
* Traws Pharma (NASDAQ:TRAW [https://seekingalpha.com/symbol/TRAW]) on Monday announced [https://seekingalpha.com/pr/20151380-traws-pharma-advances-antiviral-pipeline-with-multiple-regulatory-submissions] multiple regulatory submissions... Full story
Yahoo Finance • 3 months ago
NEWTOWN, Pa. - Traws Pharma, Inc. (NASDAQ:TRAW), a small-cap pharmaceutical company currently trading at $1.43, has submitted multiple regulatory filings to advance clinical trials for its antiviral drug candidates, according to a press re... Full story
Yahoo Finance • 3 months ago
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path... Full story
Yahoo Finance • 4 months ago
NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human healt... Full story
Yahoo Finance • 6 months ago
Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws... Full story
Yahoo Finance • 6 months ago
Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird FluRatutrelvir, a main protease inhibitor, to be used without... Full story
Yahoo Finance • 6 months ago
Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimenPreparations are underway for FDA interactions a... Full story
Yahoo Finance • 6 months ago
Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent suppression of resistant viruses and Phase 1 dataFull dataset to be highlighted during Investor... Full story
Yahoo Finance • 7 months ago
NEWTOWN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respi... Full story